| Cat.No. | Name | Information |
|---|---|---|
| M45115 | PMN310 | PMN310 is a beta-amyloid oligomer (AβO) antibody that can be used in studies related to Alzheimer's disease (AD). |
| M43951 | MK-2060 | MK-2060 is a monoclonal antibody with dual activity to inhibit coagulation factors XI and Xia, blocking both the activation of coagulation factor XI and the downstream activity of the activated protein. It can be used in studies related to end-stage renal disease (ESRD). |
| M43950 | Xisomab 3G3 | Xisomab 3G3 is a recombinant human-derived monoclonal antibody to coagulation factor XI (F11) that blocks factor XI activation mediated by factor XIIa in a concentration-dependent manner. |
| M43942 | AMG-820 | AMG-820 is an anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody. |
| M43929 | Zigakibart | Zigakibart is an anti-APRIL monoclonal antibody that can be used in studies related to IgA nephropathy (IgAN). |
| M40986 | NGM-313 | NGM-313 is a β-Klotho/FGFR1c-targeted monoclonal antibody for studies related to non-alcoholic steatohepatitis (NASH). |
| M40938 | Rat IgG2a Isotype Control In vivo | Rat IgG2a Isotype Control In vivo can be used as an isotype-matched control for rat IgG2a antibodies. |
| M40937 | Suciraslimab | Suciraslimab is a potentially first-in-class monoclonal antibody against the B-cell target CD22, which can help change CD22 from cis-binding to trans-binding and form a stable CD22 trans-binding structure, thereby restoring B-cell tolerance to its own antigens and inhibiting B-cells from undergoing a series of related immune responses to attack its own organism. |
| M40905 | Remternetug | Remternetug is an IgG1 monoclonal antibody that targets the pyroglutamate modification of the third amino acid of the amyloid beta peptide present only in brain amyloid plaques, and can be used in studies related to Alzheimer's disease (AD). |
| M40876 | Ebdarokimab | Ebdarokimab is a monoclonal antibody to IL-12p40/IL-23 that can be used in studies related to inflammatory bowel disease (IBD). |
| M40870 | RVT-3101 | RVT-3101 is a potential first-in-class anti-tumor necrosis factor (TNF)-like ligand 1A (TL1A) monoclonal antibody for use in studies related to inflammatory bowel disease (IBD). |
| M40854 | Elranatamab | Elranatamab is a humanized IgG2ҡ bispecific T-cell inducing antibody that targets CD3 and B-cell maturation antigen (BCMA) on the surface of T-cells, resulting in activation of T-cells and the release of a variety of pro-inflammatory cytokines that lead to multiple myeloma cell lysis. It can be used in studies related to relapsed or refractory multiple myeloma (RRMM). |
| M40646 | CDX-1140 | CDX-1140 is an anti-CD40 human IgG2 monoclonal antibody that activates dendritic cells and B cells and drives NF-kB stimulation in CD40-expressing reporter cell lines. |
| M40611 | PF-04236921 | PF-04236921 is a fully human IgG2 monoclonal antibody targeting the interleukin IL-6 for studies related to Crohn's disease and rheumatoid arthritis. |
| M40609 | Eblasakimab | Eblasakimab is a potential first-in-class, novel monoclonal antibody that targets the IL-13 receptor alpha 1 subunit (IL-13Rα1) and inhibits signaling of the pro-inflammatory cytokines IL-4 and IL-13. It can be used in studies related to atopic dermatitis (AD). |
| M40602 | Alacizumab | Alacizumab is a monoclonal antibody against VEGFR2 that can be used in cancer-related studies. |
| M40600 | Ebronucimab | Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia. |
| M40598 | Serclutamab | Serclutamab is a monoclonal antibody to EGFR that can be used in studies related to solid tumors. |
| M40597 | Ametumumab | Ametumumab is a recombinant fully human anti-EGFR monoclonal antibody that can be used in studies related to colorectal cancer. |
| M40596 | Pimurutamab | Pimurutamab is a monoclonal antibody to EGFR that can be used in tumor-related studies. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
